NCT02472366View on ClinicalTrials.gov

A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy

PHASE4CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

May 31, 2015

Conditions

Chronic Diabetic Macular Edema

Interventions

DRUG

ILUVIEN

Sponsors

Lead Sponsor

Alimera Sciences

All Listed Sponsors

lead

Alimera Sciences

INDUSTRY

NCT02472366 - A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy | Biotech Hunter | Biotech Hunter